The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time

Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):E4987-96. doi: 10.1073/pnas.1308313110. Epub 2013 Nov 25.

Abstract

The source and dynamics of persistent HIV-1 during long-term combinational antiretroviral therapy (cART) are critical to understanding the barriers to curing HIV-1 infection. To address this issue, we isolated and genetically characterized HIV-1 DNA from naïve and memory T cells from peripheral blood and gut-associated lymphoid tissue (GALT) from eight patients after 4-12 y of suppressive cART. Our detailed analysis of these eight patients indicates that persistent HIV-1 in peripheral blood and GALT is found primarily in memory CD4(+) T cells [CD45RO(+)/CD27((+/-))]. The HIV-1 infection frequency of CD4(+) T cells from peripheral blood and GALT was higher in patients who initiated treatment during chronic compared with acute/early infection, indicating that early initiation of therapy results in lower HIV-1 reservoir size in blood and gut. Phylogenetic analysis revealed an HIV-1 genetic change between RNA sequences isolated before initiation of cART and intracellular HIV-1 sequences from the T-cell subsets after 4-12 y of suppressive cART in four of the eight patients. However, evolutionary rate analyses estimated no greater than three nucleotide substitutions per gene region analyzed during all of the 4-12 y of suppressive therapy. We also identified a clearly replication-incompetent viral sequence in multiple memory T cells in one patient, strongly supporting asynchronous cell replication of a cell containing integrated HIV-1 DNA as the source. This study indicates that persistence of a remarkably stable population of infected memory cells will be the primary barrier to a cure, and, with little evidence of viral replication, this population could be maintained by homeostatic cell proliferation or other processes.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Retroviral Agents / administration & dosage*
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes* / metabolism
  • CD4-Positive T-Lymphocytes* / pathology
  • CD4-Positive T-Lymphocytes* / virology
  • Carrier State / virology*
  • DNA, Viral* / genetics
  • DNA, Viral* / metabolism
  • Female
  • Genome, Viral / genetics
  • HIV Infections* / drug therapy
  • HIV Infections* / genetics
  • HIV Infections* / metabolism
  • HIV Infections* / pathology
  • HIV-1* / genetics
  • HIV-1* / metabolism
  • Humans
  • Immunologic Memory
  • Lymphoid Tissue* / metabolism
  • Lymphoid Tissue* / pathology
  • Lymphoid Tissue* / virology
  • Male
  • Mutation*
  • Phylogeny
  • Time Factors

Substances

  • Anti-Retroviral Agents
  • DNA, Viral